On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization (EUA) for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in individuals aged 18 years and over.

Novavax and Taiwan have executed a supply agreement and the doses for Taiwan would represent the first shipment of Nuvaxovid to a country participating under the COVAX Facility. COVAX was established to allocate and distribute vaccines equitably to participating countries and economies.